Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Supernus Pharm 9715 Key West Avenue ROCKVILLE MD 20850 USA

www.supernus.com Employees: 674 P: 301-838-2500

Sector:

Medical

Description:

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.

Key Statistics

Overview:

Market Capitalization, $K 1,794,420
Enterprise Value, $K 1,725,090
Shares Outstanding, K 55,814
Annual Sales, $ 661,820 K
Annual Net Income, $ 73,870 K
Last Quarter Sales, $ 174,160 K
Last Quarter Net Income, $ 15,330 K
EBIT, $ 159,640 K
EBITDA, $ 241,880 K
60-Month Beta 0.83
% of Insider Shareholders 9.30%
Float, K 50,623
% Float 90.70%
Short Volume Ratio 0.52

Growth:

1-Year Return -8.59%
3-Year Return 0.37%
5-Year Return 100.06%
5-Year Revenue Growth 68.50%
5-Year Earnings Growth 25.71%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.75 on 02/25/25
Next Earnings Date 05/14/25
Earnings Per Share ttm 1.92
EPS Growth vs. Prev Qtr -35.79%
EPS Growth vs. Prev Year 2,950.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

SUPN Ratios

Ratio
Price/Earnings ttm 16.83
Price/Earnings forward 20.72
Price/Earnings to Growth N/A
Return-on-Equity % 10.96%
Return-on-Assets % 8.08%
Profit Margin % 11.16%
Debt/Equity 0.00
Price/Sales 2.73
Price/Cash Flow 7.75
Price/Book 1.72
Book Value/Share 18.76
Interest Coverage -1.31
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar